重氮环辛烷β-内酰胺酶抑制剂的作用？

IF 4.1 2区医学 Q2 MICROBIOLOGY

Antimicrobial Agents and Chemotherapy Pub Date : 2025-03-05 Epub Date: 2025-01-28 DOI:10.1128/aac.01543-24

Ava J Dorazio, Ellen G Kline, Kevin M Squires, Jason M Pogue, Daria Van Tyne, Ryan K Shields

{"title":"重氮环辛烷β-内酰胺酶抑制剂的作用？","authors":"Ava J Dorazio, Ellen G Kline, Kevin M Squires, Jason M Pogue, Daria Van Tyne, Ryan K Shields","doi":"10.1128/aac.01543-24","DOIUrl":null,"url":null,"abstract":"Paired baseline and post-exposure isolates from 34 patients who developed ceftolozane-tazobactam (TOL-TAZ) resistance following treatment of multidrug-resistant (MDR) Pseudomonas aeruginosa infections were analyzed to determine if ceftolozane with an alternative β-lactamase inhibitor could restore susceptibility. The median baseline TOL-TAZ MIC was 2 mg/L; 88% of post-exposure isolates harbored new ampC mutations. Median MIC fold-increase from baseline was 32-, 24-, 16-, and 6-fold for ceftolozane-tazobactam, ceftolozane-avibactam (AVI), ceftolozane-relebactam (REL), and ceftolozane-durlobactam (DUR), respectively. Enhanced ceftolozane-durlobactam activity was evident in specific ampC mutations.","PeriodicalId":8152,"journal":{"name":"Antimicrobial Agents and Chemotherapy","volume":" ","pages":"e0154324"},"PeriodicalIF":4.1000,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11881553/pdf/","citationCount":"0","resultStr":"{\"title\":\"Restoring ceftolozane susceptibility: a role for diazabicyclooctane β-lactamase inhibitors?\",\"authors\":\"Ava J Dorazio, Ellen G Kline, Kevin M Squires, Jason M Pogue, Daria Van Tyne, Ryan K Shields\",\"doi\":\"10.1128/aac.01543-24\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Paired baseline and post-exposure isolates from 34 patients who developed ceftolozane-tazobactam (TOL-TAZ) resistance following treatment of multidrug-resistant (MDR) Pseudomonas aeruginosa infections were analyzed to determine if ceftolozane with an alternative β-lactamase inhibitor could restore susceptibility. The median baseline TOL-TAZ MIC was 2 mg/L; 88% of post-exposure isolates harbored new ampC mutations. Median MIC fold-increase from baseline was 32-, 24-, 16-, and 6-fold for ceftolozane-tazobactam, ceftolozane-avibactam (AVI), ceftolozane-relebactam (REL), and ceftolozane-durlobactam (DUR), respectively. Enhanced ceftolozane-durlobactam activity was evident in specific ampC mutations.\",\"PeriodicalId\":8152,\"journal\":{\"name\":\"Antimicrobial Agents and Chemotherapy\",\"volume\":\" \",\"pages\":\"e0154324\"},\"PeriodicalIF\":4.1000,\"publicationDate\":\"2025-03-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11881553/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Antimicrobial Agents and Chemotherapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1128/aac.01543-24\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/28 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antimicrobial Agents and Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1128/aac.01543-24","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/28 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

对34例多药耐药（MDR）铜绿假单胞菌感染治疗后出现头孢唑氮-他唑巴坦（tolz -taz）耐药性的患者的基线和暴露后分离物进行配对分析，以确定头孢唑氮与替代β-内酰胺酶抑制剂是否可以恢复敏感性。基线TOL-TAZ MIC中位数为2 mg/L；88%的暴露后分离株携带新的ampC突变。ceftolozane-tazobactam、ceftolozane-avibactam （AVI）、ceftolozane-relebactam （REL）和ceftolozane-durlobactam （DUR）的MIC中位数较基线分别增加32、24、16和6倍。ceftolozane-durlobactam活性在特定ampC突变中明显增强。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Restoring ceftolozane susceptibility: a role for diazabicyclooctane β-lactamase inhibitors?

Paired baseline and post-exposure isolates from 34 patients who developed ceftolozane-tazobactam (TOL-TAZ) resistance following treatment of multidrug-resistant (MDR) Pseudomonas aeruginosa infections were analyzed to determine if ceftolozane with an alternative β-lactamase inhibitor could restore susceptibility. The median baseline TOL-TAZ MIC was 2 mg/L; 88% of post-exposure isolates harbored new ampC mutations. Median MIC fold-increase from baseline was 32-, 24-, 16-, and 6-fold for ceftolozane-tazobactam, ceftolozane-avibactam (AVI), ceftolozane-relebactam (REL), and ceftolozane-durlobactam (DUR), respectively. Enhanced ceftolozane-durlobactam activity was evident in specific ampC mutations.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Antimicrobial Agents and Chemotherapy 医学-微生物学

CiteScore

10.00

自引率

8.20%

发文量

762

审稿时长

3 months

期刊介绍： Antimicrobial Agents and Chemotherapy (AAC) features interdisciplinary studies that build our understanding of the underlying mechanisms and therapeutic applications of antimicrobial and antiparasitic agents and chemotherapy.